Document Detail


Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.
MedLine Citation:
PMID:  17519929     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reduced Apgar scores and birth weight, increased risk of respiratory distress, jitteriness and increased tone have been reported in up to 30% of neonates with prenatal exposure to serotonin reuptake inhibitor (SRI) antidepressant medications. In adults, effects of these medications may be related to the genotype for the serotonin transporter (SLC6A4) promoter. In this study we investigated whether SLC6A4 genotype influences the risk for adverse outcomes in neonates with prenatal SRI exposure. Neonatal outcomes including Apgar scores, birth weight, gestational age at birth, symptoms of poor neonatal adaptation and genotype for SLC6A4 were determined in 37 prenatally SRI exposed neonates and compared with 47 non-exposed neonates. Reduced 5 min Apgar scores were observed in exposed neonates and this was moderated by the ss genotype (P<0.001). Birth weight was lower in exposed ls neonates (P=0.008). Risk for respiratory symptoms (respiratory distress and rapid breathing) was higher in exposed neonates with the ll genotype compared to non-exposed neonates (P<0.05) and risk for neuromotor symptoms increased in exposed ss neonates (P<0.026). These relationships remained when controlling for maternal mood during pregnancy, length of gestational medication exposure and gestational age at birth and cesarean section rate. Prenatal SRI exposure was associated with adverse neonatal outcomes and these effects were moderated by infant SLC6A4 genotype. Relationships between polymorphisms and specific outcomes varied during the neonatal period, suggesting that beyond apparent gene-medication interactions, multiple mechanisms contribute to adverse neonatal outcomes following prenatal SRI exposure.
Authors:
T F Oberlander; R J Bonaguro; S Misri; M Papsdorf; C J D Ross; E M Simpson
Related Documents :
15121939 - Immune parameters and morbidity in hard drug and human immunodeficiency virus-exposed b...
20832329 - Maternal cigarette smoking and the associated risk of having a child with orofacial cle...
1992399 - Brain growth among fetuses exposed to cocaine in utero: asymmetrical growth retardation.
17943979 - Individual differences in salivary cortisol and alpha-amylase in mothers and their infa...
6768869 - Ventilatory response to carbon dioxide of infants following chronic prenatal methadone ...
8424009 - Cocaine use in women from a defined population: prevalence at delivery and effects on g...
12850349 - Mechanisms by which maternal antibodies influence infant vaccine responses: review of h...
6679149 - Serological evidence of ureaplasma urealyticum infection in neonatal respiratory disease.
15203259 - Elevated serum cardiac troponin i in rhabdomyolysis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-05-22
Journal Detail:
Title:  Molecular psychiatry     Volume:  13     ISSN:  1359-4184     ISO Abbreviation:  Mol. Psychiatry     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-17     Completed Date:  2008-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607835     Medline TA:  Mol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  65-73     Citation Subset:  IM    
Affiliation:
Early Human Experience Unit, Department of Pediatrics, Centre for Community Child Health Research, University of British Columbia, Vancouver, BC, Canada. toberlander@cw.bc.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptation, Physiological / drug effects
Adult
Anxiety Disorders / blood,  drug therapy
Apgar Score
Birth Weight / drug effects*
Case-Control Studies
Chi-Square Distribution
Cohort Studies
Depressive Disorder / blood,  drug therapy
Female
Gestational Age
Humans
Infant Behavior / drug effects*,  physiology
Infant, Newborn
Male
Maternal-Fetal Exchange*
Polymorphism, Genetic
Pregnancy
Pregnancy Outcome
Prenatal Exposure Delayed Effects*
Reference Values
Risk Assessment
Serotonin Plasma Membrane Transport Proteins / drug effects,  genetics*
Serotonin Uptake Inhibitors / blood,  pharmacology*,  therapeutic use
Chemical
Reg. No./Substance:
0/SLC6A4 protein, human; 0/Serotonin Plasma Membrane Transport Proteins; 0/Serotonin Uptake Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differenc...
Next Document:  A current perspective on the role and needs of IACUC unaffiliated members.